Published in Fed Proc on March 14, 1970
The selective action of antilymphocyte serum on recirculating lymphocytes: a review of the evidence and alternatives. Clin Exp Immunol (1970) 1.76
The cellular origin of the lymphochte trap. Immunology (1974) 1.27
Depletion of lymphoid tissues by tilorone. Ultrastructure and synergistic interaction with antilymphocyte serum. Am J Pathol (1983) 0.75
The effect of localized injection of adjuvant material on the draining lymph node. II. Circulating lymphocytes. Immunology (1970) 2.19
Segregation of lymphocyte populations through differential migration. Nature (1969) 2.09
The effect of localized injection of adjuvant material on the draining lymph node. I. Histology. Immunology (1970) 2.00
Notes on the preparation and assay of anti-lymphocytic serum for use in mice. Immunology (1968) 1.96
Immunologic dysfunction in heroin addicts. Arch Intern Med (1974) 1.77
Histopathological effects in mice of heterologous antilymphocyte serum. J Exp Med (1968) 1.61
Effects of heterologous anti-lymphocyte serum on the distribution of 51-Cr-labelled lymph node cells in mice. Immunology (1968) 1.52
Imparied lymphocyte responsiveness in inflammatory bowel disease. Gastroenterology (1973) 1.51
The effect of localized injection of adjuvant material on the draining lymph node. 3. Thymus dependence. J Immunol (1972) 1.48
Architectural organization in the interphase nucleus of the protozoan Trypanosoma brucei: location of telomeres and mini-chromosomes. EMBO J (1990) 1.44
Short-term lymphocyte cultures in regional enteritis. Lancet (1970) 1.43
Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy. Cancer Res (1991) 1.40
Anergy to dinitrochlorobenzene and depression of T-lymphocytes in Crohn's disease and ulcerative colitis. Gut (1976) 1.38
Effects of lymphoid depletion on the distribution of 51Cr-labeled lymph node cells in mice. Transplantation (1971) 1.23
Distribution of labeled lymph node cells in mice during the lymphocytosis induced by Bordetella pertussis. J Exp Med (1972) 1.14
Effect of verapamil and other agents on the distribution of anthracyclines and on reversal of drug resistance. Cancer Res (1987) 1.11
Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells. Cancer Res (1989) 1.09
T and B lymphocytes and cutaneous anergy in inflammatory bowel disease. Ann N Y Acad Sci (1976) 1.07
Chemotherapy for advanced sarcoma: therapeutic decisions and modalities. Semin Oncol (1997) 1.06
Isolation and characterization of an anthracycline-resistant human leukemic cell line. Cancer Res (1985) 1.03
Role of glutathione and dependent enzymes in anthracycline-resistant HL60/AR cells. Cancer Res (1989) 1.02
Assessment of potential exposure to antineoplastic agents in the health care setting. Prev Med (1984) 0.97
Hematologic and immunologic aspects of parabiosis. Mt Sinai J Med (1976) 0.94
Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors. Oncogene (2006) 0.91
Letter: Lymphocyte responsiveness in inflammatory bowel disease. Gastroenterology (1975) 0.91
Immunologic diagnosis and monitoring of human acute leukemias: a review. Am J Pathol (1981) 0.90
Immunotherapy with dinitrochlorobenzene (DNCB) for recurrent squamous cell tumor of conjunctiva. Trans Am Ophthalmol Soc (1976) 0.89
Specific impairment of humoral and cellular allograft immunity after splenic allotransplantation in rats. Transplant Proc (1977) 0.88
Immunologic aberrations in the Di Guglielmo syndrome. Blood (1966) 0.87
Immunotherapy of human cancer. Prog Allergy (1973) 0.87
Specificity of heteroantisera to human acute leukemia-associated antigens. J Clin Invest (1974) 0.87
Induction of granulomas in mice by inoculation of tissue homogenates from patients with inflammatory bowel disease and sarcoidosis. Ann N Y Acad Sci (1976) 0.86
Isolation and partial characterization of radioiodinated myeloblastic leukemia-associated cell surface glycoprotein antigen. Cancer Res (1978) 0.85
Transmission of ileitis and sarcoid granulomas to mice. Trans Assoc Am Physicians (1974) 0.85
Prolongation of skin homograft survival by mouse-anti-mouse thymocyte isoantiserum. Transplant Proc (1969) 0.84
Cyclophosphamide-induced immunologic tolerance to skin homografts. Surg Forum (1971) 0.84
Delayed cutaneous hypersensitivity in leukaemic patients to autologous blast cells. Br J Haematol (1974) 0.84
Characterization of compounds shed from the surface of human leukemic myeloblasts in vitro. Blood (1982) 0.84
Editorial: A transmissible agent in Crohn's disease? New pursuit of an old concept. N Engl J Med (1975) 0.84
Effects of pyrimidine antagonists on sialic acid regeneration in HL-60 cells. Cancer Res (1985) 0.83
Peripheral blood lymphocyte subpopulations in sarcoidosis. Cell Immunol (1975) 0.83
Serologic characterization of a monkey antiserum to human leukemic myeloblasts. Blood (1980) 0.83
Masking of neutrophil surface lectin-binding sites in chronic myelogenous leukemia (CML). Blood (1980) 0.83
Mechanisms and kinetics of cyclophosphamide-induced specific tolerance to skin allografts in mice. Transplant Proc (1973) 0.82
Antigen-induced immunological tolerance in man to equine anti-human-thymocyte gamma-globulin. Lancet (1969) 0.82
Effect of thymus enclosed in millipore diffusion envelopes on thymectomized hamsters. Blood (1966) 0.81
Significance of anergy to dinitrochlorobenzene (DNCB) in inflammatory bowel disease: family and postoperative studies. Gut (1978) 0.81
In vivo effects of concanavalin A. I. Immunosuppressive effects. Transplantation (1972) 0.81
Transpulmonary water exchange in newborn lambs under artificial placentation. Am J Physiol (1966) 0.80
Effects of concanavalin A on the migration of radioactively labeled lymphoid cells. Cell Immunol (1974) 0.80
Changes in the granulocyte membrane following chemotherapy for chronic myelogenous leukaemia. Br J Haematol (1986) 0.80
Letter: B lymphocytes in inflammatory bowel disease. Lancet (1974) 0.79
Two-stage operative cytoreduction and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: Operative morbidity and mortality in phase I and II trials. Eur J Surg Oncol (2010) 0.79
Increased activity of a specific sialyltransferase in chronic myelogenous leukemia. Blood (1985) 0.79
Membrane glycoprotein changes associated with anthracycline resistance in HL-60 cells. Cancer Chemother Pharmacol (1991) 0.78
Phase II trial of the dopaminergic inhibitor pimozide in previously treated melanoma patients. Cancer Treat Rep (1983) 0.78
Monosaccharide inhibition of E-rosette formation. Clin Immunol Immunopathol (1980) 0.78
Platelets--cyclophosphamide-induced immunological tolerance to skin allografts in mice. Transplantation (1974) 0.78
Myeloblastic and lymphoblastic markers in acute undifferentiated leukemia and chronic myelogenous leukemia in blast crisis. Cancer Res (1980) 0.77
Production of antiserum in mice to human leukaemia-associated antigens. Nat New Biol (1973) 0.77
Treatment of metastatic malignant melanoma with pimozide. Lancet (1979) 0.76
Effects of dopamine agonists and antagonists on murine melanoma: correlation with dopamine binding activity. Cancer (1982) 0.76
Antibody responses to leukemia-associated antigens during immunotherapy of chronic myelocytic leukemia. Blood (1975) 0.76
Aberrant sialylation of granulocyte membranes in chronic myelogenous leukemia. Blood (1984) 0.76
Differences in daunomycin retention in sensitive and resistant P388 leukemic cells as determined by digitized video fluorescence microscopy. Cancer Res (1983) 0.76
B.C.G. in malignant melanoma. Lancet (1973) 0.75
Early diagnosis of relapse in acute myeloblastic leukemia: Serologic detection of leukemia-associated antigens in human marrow. N Engl J Med (1979) 0.75
Platelet-induced tolerance in the production of heteroantisera to human leukemia-associated antigens. J Immunol Methods (1976) 0.75
Microsurgical renal transplantation techniques in small animals. Invest Urol (1977) 0.75
Immunotherapy for chronic myelogenous leukemia: survival not affected by treatment in the stable phase. Cancer Res (1984) 0.75
Immunotherapy of human acute leukemia: antibody response to leukemia-associated antigens. Blood (1978) 0.75
In vivo effects of Concanavalin A. II. Distribution, histopathologic changes, and toxicity. Mt Sinai J Med (1976) 0.75
The kinetic behaviour of transfused donor bone marrow neutrophils and their precursors in neutropenic patients. Br J Haematol (1973) 0.75
William Dameshek, M.D., 1900-1969. Mt Sinai J Med (1970) 0.75
Treatment of anthracycline extravasation--a warning against the use of sodium bicarbonate. J Clin Oncol (1987) 0.75
Amelioration of streptozotocin-induced diabetes in mice by the implantation of pancreatic islets in diffusion chambers. Mt Sinai J Med (1976) 0.75
Regeneration of membrane sialic acid after neuraminidase treatment of leukemic granulocytes. Leuk Res (1985) 0.75
Homogeneously staining region in anthracycline-resistant HL-60/AR cells not associated with MDR1 amplification. Cancer Res (1992) 0.75
Paradoxical effect of operative ischemia time on rat renal allograft survival. Surg Forum (1974) 0.75
Comparison of the adjuvant effect of three BCG preparations in mice. Oncology (1978) 0.75
Induction of tolerance to skin homografts with a methylhydrazine derivative. Synergism with antilymphocytic serum and morphologic responses of the lymphoid system. Agents Actions (1970) 0.75
Alloantisera to human leukemic blast cells: detection of leukemia-associated antigens (LAA). Prog Clin Biol Res (1977) 0.75
Prolongation of rat renal allograft survival by cyclophosphamide and intravenous donor-specific antigens. Eur Surg Res (1977) 0.75
Human leukemic myeloblasts and myeloblastoid cells contain the enzyme cytidine 5'-monophosphate-N-acetylneuraminic acid:Gal beta 1-3GalNAc alpha (2-3)-sialyltransferase. Cancer Res (1990) 0.75
Human acute myelogenous leukemia-associated antigens defined by a monkey antiserum to glycoproteins shed from leukemia myeloblasts. Leuk Res (1981) 0.75
Influence of cell surface galactosyl determinants on splenic localization of mouse thymocytes. Transplantation (1980) 0.75
The Columbia Cancer Center Cancer Control Program. Prog Clin Biol Res (1983) 0.75
Grand rounds: the mask of chronic granulocytic leukemia. Va Med (1979) 0.75
Enteric migration of radiolabeled lymphocytes. Cell Immunol (1976) 0.75
Development of an interactive inter-state community hospital based regional tumor registry. Prog Clin Biol Res (1983) 0.75
Adaptation of skin allografts in mice treated with antilymphocyte serum. Transplantation (1972) 0.75
Letter: Normarski optics and T and B markers. Lancet (1975) 0.75
Immunotherapy of human leukemia. Mt Sinai J Med (1973) 0.75
Prolonged survival of skin allografts from uremic mice. Transplantation (1974) 0.75
Lymphocyte kinetics and lymphoid tissue morphology accompanying immunosuppression by antilymphocyte serum (ALS). Antibiot Chemother (1969) 0.75
Adjuvant immunotherapy for vulvar malignant melanoma. Mt Sinai J Med (1979) 0.75
Five-year follow-up of immunotherapy in acute lymphoblastic leukaemia. Lancet (1977) 0.75
Induction of secific immunological tolerance to histocompatible renal and skin allografts after donor strain spleen implantation. Proc Eur Dial Transplant Assoc (1976) 0.75
Mechanisms of immunosuppression by antilymphocyte antibody. Pathobiol Annu (1972) 0.75